Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease

Journal of Medicinal Chemistry

Volumn 45, Issue 24, 2002, Pages 5260-5279

  Sterling, Jeffrey ^a,b   Herzig, Yaacov ^a,b   Goren, Tamar ^a,b   Finkelstein, Nina ^a,b   Lerner, David ^a,b   Goldenberg, Willy ^a,b   Miskolczi, Istvan ^c   Molnar, Sandor ^c   Rantal, Ferenc ^c   Tamas, Tivadar ^c   Toth, Gyorgy ^c   Zagyva, Adela ^c   Zekany, Andras ^c   Lavian, Gila ^d   Gross, Aviva ^d   Friedman, Rachel ^d   Razin, Michal ^e   Huang, Wei ^e   Krais, Boris ^e   Chorev, Michael ^f   Youdim, Moussa B ^d   Weinstock, Marta ^e   more..

^a Teva Pharmaceutical Industries   (Israel)

^b TEVA PHARMACEUTICALS   (Israel)

^c Biogal Inc   (Hungary)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOTETRALIN; 4 CARBAMOYLOXYPHENYL; 6 CARBAMYLOXYPHENYL; 7 CARBAMYLOXYPHENYL; AMINE; BENZENE DERIVATIVE; CARBAMIC ACID; CHEMICAL COMPOUND; CHOLINESTERASE INHIBITOR; HYDROXYAMINOINDAN; HYDROXYL GROUP; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PHENETHYLAMINE; PHENOL DERIVATIVE; PROPARGYL; PROPARGYLAMINE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; ENZYME BINDING; HUMAN; METHYLATION; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BINDING SITES; BUTYRYLCHOLINESTERASE; CARBAMATES; CATTLE; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARGYLINE; PHENETHYLAMINES; PROPYLAMINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037153195     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020120c     Document Type: Article

References (70)

1. Coyle, J. T.; Price, D. L.; DeLong, M. R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983, 219, 1184-90.
2. Newman, S. C. The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample. J. Affect. Disord. 1999, 52, 169-176.
3. Palmer, A. M.; Stratman, G. C.; Procter, A. W.; Bowen, D. M. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann. Neurol. 1988, 23, 616-20.
4. Good, P. F.; Werner, P.; Hsu, A.; Olanow, C. W.; Perl, D. P. Evidence for neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 1996, 149, 21-28.
5. Saura, J.; Luque, J. M.; Cesura, A. M.; Da Prada, M.; ChanPalay, V.; Hu Loffler, J.; Richards, J. G. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative radioautography. Neuroscience 1994, 62, 15-30.
6. Weinstock, M. Selectivity of Cholinesterase inhibition: Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999, 12, 307-323.
7. Sano, M.; Ernesto, C.; Thomas, R. G.; Klauber, M. R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C. W.; Pfeiffer, E.; Schneider, L. S.; Thal, L. J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for alzheimer's disease. N. Engl. J. Med. 1997, 336, 1216-1222.
8. Abu-Raya, S.; Blaugrund, E.; Trembovler, V.; Shilderman-Bloch, E.; Shohami, E.; Lazarovici, P. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differenciated PC12 cells against oxygen-glucose deprivation. J. Neurosci. Res. 1999, 58, 456-463.
9. Paterson, I. A.; Tatton, W. G. Antiapoptotic actions of monoamine oxidase B inhibitors. Adv. Pharmacol. 1998, 42, 312-5.
10. Youdim, M. B.; Wadia, A.; Tatton, W.; Weinstock, M. The antiparkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. NY Acad. Sci. 2001, 939, 450-8.
11. O'Malley, G.; Bores, G.; Huger, F.; Kurys, B.; Merriman, M.; Olsen, G.; Ong, H.; Petko, W.; Palermo, M. Synthesis and biological evaluation of combined AChE and MAO inhibitors. Abstracts of Papers, 205th American Chemical Society National Meeting, 1993; American Chemical Society: Washington, DC, 1993; MEDI, abstract.
12. Fink, D. M.; Palermo, M. G.; Bores, G. M.; Huger, F. P.; Kurys, B. E.; Merriman, M. C.; Olsen, G. E.; Petko, W.; O'Malley, G. J. Imino 1,2,3,4-tetrahydrocyclopent[b]-indole carbamates as dual inhibitors of acetylcholinesterase and monoamine oxidase. Bioorg. Med. Chem. Lett. 1996, 6, 625-630.
13. Palermo, M.; Bores, G.; Huger, F.; Kurys, B.; Merriman, M.; Olsen, G.; Ong, H.; Petko, W.; O'Malley, G. Combined AChE and reversible MAO inhibition as a potential therapeutic approach for senile dementia of the Alzheimer type. Abstracts of Papers, 205th American Chemical Society National Meeting, 1993; American Chemical Society: Washington, DC, 1993; MEDI, abstract.
14. Kimura, T.; Kuroki, Y. Pyrimidine compound. EP 664291 (UBE Industries, 1994).
15. Bruhlmann, C.; Ooms, F.; Carrupt, P.-A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem. 2001, 44, 3195-3198.
16. Knollema, S.; Aukema, W.; Hom, H.; Korf, J.; Horst, G. J.T. L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 1995, 26, 1883-1887.
17. Lahtinen, H.; Koistinaho, J.; Kauppinen, R.; Haapalinna, A.; Keinanen, R.; Sivenius, J. Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus. Brain Res. 1997, 757, 260-267.
18. inberg, J. P. M.; Takeshima, T.; Johnston, J. M.; Commissiong, J. W. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase-B inhibitor. NeuroReport 1998, 9, 703-707.
19. Huang, W.; Chen, Y.; Shohami, E.; Weinstock, M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 1999, 366, 127-135.
20. Gulinnaz, A.; Girgin, F. K.; Ozgonul, M.; Mentes, G.; Ersoz, B. MAO inhibitors and oxidant stress in aging brain tissue. Eur. Neuropsychopharmacology 1999, 9, 247-252.
21. Dostert, P.; O'Brien, E. M.; Tipton, K. F.; Meroni, M.; Melloni, P.; Strolin, M.; Benedetti, M. Inhibition of monoamine oxidase by the R and S enantiomers of N[3-(2,4-dichlorophenoxy)-propyl]-N-methyl-3-butyn-2-amine. Eur. J. Med. Chem. 1992, 27, 45-52.
22. Kawasaki, I.; Matsuda, K.; Kaneko, T. Preparation of 1,7-bis(p-hydroxyphenyl) heptane. Bull. Chem. Soc. Jpn. 1971, 44, 1986-7.
23. Oshiro, Y.; Sakurai, Y.; Tanaka, T.; Ueda, H.; Kikuchi, T.; Tottori, K. Novel cerebroprotective agents with CNS stimulating activity. 1. Synthesis and pharmacology of the 1-amino-7-hydroxyindan derivatives. J. Med. Chem. 1991, 34, 2004-13.
24. Borch, R. F.; Bernstein, M. D.; Durst, H. D. The cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 1971, 93, 2897-2904.
25. Cannon, J. G.; Dushin, R. G.; Long, J. P.; Ilhan, M.; Jones, N. D.; Swartzendruber, J. K. Synthesis and dopaminergic activity of (R) and (S)-4-Hydroxy-2-(Di-n-propylamino)indan. J. Med. Chem. 1985, 28, 515-18.
26. Singh, T.; Stein, R. G.; Hoops, J. F.; Biel, J. H.; Hoya, W. K.; Cruz, D. R. Antimalarials. 7-chloro-4-(substituted amino)-quinolines. J. Med. Chem. 1971, 14, 283-286.
27. Huebner, C. F.; Donoghue, E. M.; Plummer, A. J.; Furness, P. A. N-methyl-N-2-propynyl-1-indanamine, a potent MAO inhibitor. J. Med. Chem. 1966, 9, 830-832.
28. Toth, G., unpublished results.
29. Lidor, R.; Bahar, E. Method for Preparing Optically Active 1-Aminoindan Derivatives. US 5639913, 1997.
30. Teranishi, K.; Nakatsuka, S.; Goto, T. Facile synthesis of 6-hydroxyindole and 6-methoxyindole via regioselective friedel-crafts acylation and baeyer-villiger oxidation. Synthesis 1994, 1018-20.
31. (a) Riggs, R. M.; Nichols, D. E.; Foreman, M. M.; Truex, L. L. Evaluation of isomeric 4-(chlorohydroxyphenyl)-1,2,3,4-tet-rahydroisoquinolines as dopamine D-1 antagonists. J. Med. Chem. 1987, 30, 1887-1889.
32. (b) Ginsburg D. The action of tertbutyl hypochlorite on organic compounds. II. Aromatic aldehydes. J. Am. Chem. Soc. 1951, 73, 702-704.
33. Toth, G.; Kover, K. E. Simple, safe, large scale synthesis of 5-arylmethyl-2,2-dimethyl-1,3-dioxane-4,6-diones and 3-arylpropanoic acids. Synth. Commun. 1995, 25, 3067-3074.
34. Meldrum, A. N. A β-Lactonic Acid from Acetone and Malonic Acid. J. Chem. Soc. 1908, 93, 598-601.
35. Davidson, D; Bernhard, S. A. The structure of meldrum's supposed β-lactonic acid. J. Am. Chem. Soc. 1948, 70, 3426-8.
36. Demir, A. S.; Tanyeli, C.; Sesenoglu, O.; Demic, S.; Evin, O. O. A simple synthesis of 1-aminophosphonic acids from 1-hydroxy-iminophosphonates with NaBH4 in the presence of transition metal compounds. Tetrahedron Lett. 1996, 37, 407-410.
37. Copinga, S.; Tepper, P.; Grol, C. J.; Horn, A. S.; Dubocovich, M. L. 2-amino-8-methoxytetralins: A series of nonindolic melatonin-like agents. J. Med. Chem. 1993, 36, 2891-98.
38. Ellenstein, A.; Ringel, I. (School of Pharmacy, the Hebrew University, Jerusalem, Israel), unpublished results, personal communication.
39. Weinstock, M.; Razin, M.; Ringel, I.; Tashma, Z.; Chorev, M. Acetylcholinesterase inhibition by novel carbamates: A kinetic and NMR study. In Multidiscipinary Approaches to Cholinesterase Functions, 36th; Shafferman, A., Velan, B., Eds.; Plenum: New York, NY, 1992; pp 251-9.
40. Buck, J. S.; Baltzly, R.; Ide, W. S. β-phenylethylamine derivatives. Tertiary and quaternary salts. J. Am. Chem. Soc. 1938, 60, 1789-92.
41. Organic Syntheses; Wiley: New York, 1963; Collect. Vol. IV, pp 573-6.
42. Carlsson, A.; Lindquist, M.; Wysokowski, J. Substituted metatyramines as brain monoamine depletors. Acta Pharm. Suecica 1970, 7, 293-302.
43. Acid addition Salts of D-(+)-l-(3-Hydroxyphenyl)-2-Aminopropane and their Manufacture and Use. GB 1527479, 1977.
44. Saari, W. S.; Raab, A. W.; Engelhardt, E. L. The Stereoisomers of alpha-(1-aminoethyl)-M-hydroxybenzyl alcohol. J. Med. Chem. 1968, 11, 1115-7.
45. Buckley, T. F., III; Rapoport, H. α-Amino acids as chiral educts for asymmetric products. Amino acylation with N-acylamino acids. J. Am. Chem. Soc. 1981, 103, 6157-63.
46. Marco, J. L.; Royer, J.; Husson, H.-P. Asymmetric synthesis IX: Preparation of chiral α-substituted phenethylamines. Synth. Commun. 1987, 17, 669-76.
47. Weinstock, M.; Razin, M.; Chorev, M.; Tashma, Z. Pharmacological activity of novel anticholinesterase agents of potential use in treatment of Alzheimer's disease. J. Neural Transm. 1994, s43, 219-225.
48. Harel, M.; Sussman, J. L.; Krejci, E.; Bon, S.; Chanal, P.; Massoulie, J.; Silman, I. Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 10827-10831.
49. Lieske, C. N.; Gepp, R. T.; Clark, J. H.; Meyer, H. G.; Blumberg, P.; Tseng, C. C. Anticholinesterase activity of potential therapeutic 5-(1,3,3-trimethylindolinyl) carbamates. J. Enzyme Inhib. 1991, 5, 215-223.
50. Iyo, M.; Namba, H.; Fukushi, K.;. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997, 349, 1805-1809.
51. Arendt, T.; Bruckner, M.; Lange, M.; Bigl, V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - A study of molecular forms. J. Neurochem. 1992, 21, 231-244.
52. Bolognesi, M. L.; Andrisano, V.; Bartolini, M.; Minarini, A.; Rosini, M.; Tumiatti, V.; Melchiorre, C. Hexahydrochromeno[4,3-b]pyrrole derivatives as AChE inhibitors. J. Med. Chem. 2001, 44, 105-9.
53. Bar-On, P.; Millard, C. B.; Harel, M.; Dvir, H.; Enz, A.; Sussman, J. L.; Silman, I. Kinetic and Structural Studies on the Interaction of Cholinesterases with the Anti-Alzheimer Drug Rivastigmine. Biochemistry, 2002, 41, 3555-64, was published while this manuscript was in the final stages of submission. In their crystal structure, the rivastigmine carbamoyl bond has already been cleaved and the two fragments (NAP and carbamoyl) are bound by the enzyme some distance from one another. Thus, it is impossible to reconstruct the conformation of rivastigmine at the time of initial binding. Although the 4-hydroxy dimethylaminoindan resulting from 32a superimposes more successfully on their NAP, there is no apparent reason that 6-hydroxy aminoindan from 31a will not also fit in the site. We are continuing to investigate this issue.
54. Hazelhoff, B.; De Vries, J. B.; Dijkstra, D.; de Jong, W.; Horn, A. S. The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: A potent monoamine oxidase inhibitor. Naunyn-Schmiedeberg's Arch. Pharmacol. 1985, 330, 50-58.
55. Sterling, J.; Veinberg, A.; Lerner, D.; Goldenberg, W.; Levy, R.; Youdim, M.; Finberg, J. (R) (+)-N-propargyl-1-aminoindan (Rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B. J. Neural Transm. [Suppl] 1998, 52, 301-305.
56. Binda, C.; Newton-Ginson, P.; Hubalek, F.; Edmondson, D. E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nature Struct. Biol. 2002, 9, 22, was published while this manuscript was in the final stages of submission.
57. Kalir, A.; Sabbagh, A.; Youdim, M. B. H. Selective acetylenic 'suicide' and reversible inhibitors of MAO types A and B. Br. J. Pharmacol. 1981, 73, 55-64.
58. Riederer, P.; Reynolds, G. P.; Youdim, M. B. H.; Jellinger, K. In vitro tests of MAO inhibitors in human brain tissue: Chemical structure and pharmacological action. Int. Congr. Ser.-Excerpta Med. 1982, 564 (MAO), 345-350.
59. Polymeropoulos, P. l-deprenyl: A unique MAO-B inhibitor. In Inhibitors of MAO B, Pharmacology and Clinical Use in Neurodegenerative Disorders; Szelenyi, I. Ed.; Birkhauser Verlag: Basel, 1993.
60. Moron, J. A.; Campillo, M; Perez, V.; Unzeta, M.; Pardo, L. Molecular determinants of MAO selectivity in a series of indolylmethylamine derivatives: Biological activities, 3D-QSAR/CoMFA analysis, and computational simulation of ligand recognition. J. Med. Chem. 2000, 43, 1684-1691.
61. 3) decreased A activity by a factor of 2 and B by a factor of 10. All of these compounds are A selective by factors ranging from 2 to 200.
62. Swett, L. R.; Martin, W. B.; Taylor, J. D.; Everett, G. M.; Wykes, A. A.; Gladish, Y. C. Structure-activity relations in the pargyline series. Ann. N.Y. Acad. Sci. 1963, 891-898.
63. Borbe, H.; Niebch, G.; Nickel, B. Kinetic evaluation of MAO-B activity following oral administration of selegiline and desmethyl selegiline in rat. J. Neural Transm. 1990, 32 (suppl) 131-7.
64. Maycock, A. L.; Abeles, R. H.; Salch, J. I.; Singer, T. P. The action of acetylenic inhibitors on mitochondrial monoamine oxidase: Structure of the flavin site in the inhibited enzyme. In Monoamine Oxidase and its Inhibition; Wolstenholme, G. E. W., Knight, J., Eds.; Elsevier: Amsterdam, 1976; pp 33-47.
65. Rudenko, V. A.; Yakubovitsch, A. Y.; Nikiforova, T. Y. J. Gen. Chem. USSR (Engl. Transl.) 1947, 17, 2256.
66. McGhee, W. D.; Pan, Y.; Talley, J. J. Conversion of amines to carbamoyl chlorides using carbon dioxide as a phosgene replacement. Tetrahedron Lett. 1994, 35, 839-842.
67. Lieber, E.; Rao, C. N. R.; Layer, C. B.; Trivedi, J. P. 5-(disubstituted) amino-1,2,3,4-thiatriazoles. Can. J. Chem. 1963, 41, 1643-1644.
68. Lidor, R.; Bahar, E.; Zairi, O.; Atili, G.; Amster, D. A facile synthesis for racemic and optically active 1-aminoindans. Org. Prep. Proced. Int. 1997, 29, 701-706.
69. Ellman, G. L.; Courtney, K. D.; Anders, F.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.
70. Tipton, K. F.; Youdim, M. B. H. The assay of monoamine oxidase activity. In Methodes in Biogenic Amine Research; Parvez, S., Nagatsu, T., Nagatsu, I.; Parvez, H., Eds.; Elsevier: Amsterdam, 1983; pp 441-467.